<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ENOXACIN</span><br/>(e-nox'a-sin)<br/><span class="topboxtradename">Penetrex<br/></span><b>Classifications:</b> <span class="classification">antiinfective antibiotic, quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg, 400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic quinolone broad-spectrum antibiotic. Inhibits DNA-gyrase, an enzyme necessary for bacterial DNA replication and
         some aspects of transcription, repair, recombination, and transposition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against <i>Neisseria gonorrhoeae, Escherichia coli, Staphylococcus epidermidis, Staphylococcus saprophyticus, Klebsiella pneumoniae,
            Proteus mirabilis, Pseudomonas aeruginosa</i>, and <i>Enterobacter cloacae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Uncomplicated urethral or cervical gonorrhea and uncomplicated and complicated urinary tract infections due to susceptible
         organisms.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Ear, nose, and throat infections, lower respiratory tract infections, and skin infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to enoxacin, ciprofloxacin, or other quinolones; pregnant women (category X), lactation, and children.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe renal impairment and known or suspected CNS disorders.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200400 mg q12h for 714 d<br/><br/><span class="indicationtitle">Uncomplicated Gonorrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg single dose<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>CL<sub>cr</sub> <img src="../images/special/lesserorequal.gif"/>30 mL/min: Reduce dose by 50%<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after meals.</li>
<li>Keep patient well hydrated.</li>
<li>Lower dose for patients with renal impairment according to Cl<sub>cr</sub>.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, hallucinations, seizures. <span class="typehead">GI:</span> Nausea, vomiting, gastric pain. <span class="typehead">Skin:</span> Rash, photosensitivity. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Ranitidine</b> may decrease enoxacin levels by 40% when given 2 h before enoxacin. Enoxacin decreases <b>theophylline</b> clearance by at least 50%, thus increasing <b>theophylline</b> levels and toxicity. <span class="classification">aluminum- and magnesium-containing antacids</span> may decrease the absorption of enoxacin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 90% of dose reaches systemic circulation. <span class="typehead">Peak:</span> Serum, 12 h; urine, 2.57 h. <span class="typehead">Distribution:</span> Widely distributed including blister fluid, middle ear fluid, and prostatic tissue; crosses placenta; distributed into breast
      milk. <span class="typehead">Metabolism:</span> 1520% of dose metabolized in liver. <span class="typehead">Elimination:</span> 2672% excreted in urine within 72 h. <span class="typehead">Half-Life:</span> 36 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine C&amp;S prior to initial dose. Treatment may be started pending results.</li>
<li>Discontinue the drug immediately and notify physician for hypersensitivity reaction, including skin rash or other allergic
            response; may occur after just one dose.
         </li>
<li>Monitor for increased digoxin level and possible toxicity with concurrent digoxin administration.</li>
<li>Monitor patients with seizure disorders carefully, since enoxacin may lower the seizure threshold.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and notify physician promptly at first sign of an allergic response.</li>
<li>Restrict caffeine intake; enoxacin may reduce rate of caffeine clearance, producing insomnia, nervousness, tachycardia.</li>
<li>Phototoxicity may occur with excessive exposure to sunlight.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>